ID

39729

Description

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection; ODM derived from: https://clinicaltrials.gov/show/NCT01685203

Lien

https://clinicaltrials.gov/show/NCT01685203

Mots-clés

Versions (1)
  1. 13/02/2020 13/02/2020 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

13 février 2020

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Hepatitis C, Chronic NCT01685203

Anglais

Eligibility Hepatitis C, Chronic NCT01685203

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
females must be practicing specific forms of birth control on study treatment, or be postmenopausal for more than 2 years or surgically sterile
Description

Gender Contraceptive methods | Postmenopausal state Duration

Type de données

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0700589
UMLS CUI [2,1]
C0232970
UMLS CUI [2,2]
C0449238
subjects must meet one of the following:
Description

Criteria Quantity Fulfill

Type de données

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C1550543
treatment-naive: subject has never received antiviral treatment for hepatitis c infection or
Description

Therapy naive | Antiviral Therapy Absent Hepatitis C

Type de données

boolean

Alias
UMLS CUI [1]
C0919936
UMLS CUI [2,1]
C0280274
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0019196
treatment experienced (prior null responders, partial responders or relapsers to pegifn/rbv);
Description

Therapeutic procedure Experience | Non-responder PEGINTERFERON/RIBAVIRIN | Partial responder PEGINTERFERON/RIBAVIRIN | Relapse PEGINTERFERON/RIBAVIRIN

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0596545
UMLS CUI [2,1]
C0919875
UMLS CUI [2,2]
C1875630
UMLS CUI [3,1]
C4285679
UMLS CUI [3,2]
C1875630
UMLS CUI [4,1]
C0035020
UMLS CUI [4,2]
C1875630
body mass index (bmi) is ≥ 18 to < 38 kg/m^2.
Description

Body mass index

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
chronic hcv genotype 1b infection/with or without cirrhosis or hcv genotype 4 infection/without cirrhosis for at least 6 months prior to study screening.
Description

Chronic Hepatitis C Genotype Duration | Liver Cirrhosis | Liver Cirrhosis Absent | Hepatitis C Genotype Duration | Liver Cirrhosis Absent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0524910
UMLS CUI [1,2]
C1533728
UMLS CUI [1,3]
C0449238
UMLS CUI [2]
C0023890
UMLS CUI [3,1]
C0023890
UMLS CUI [3,2]
C0332197
UMLS CUI [4,1]
C0019196
UMLS CUI [4,2]
C1533728
UMLS CUI [4,3]
C0449238
UMLS CUI [5,1]
C0023890
UMLS CUI [5,2]
C0332197
subject has plasma hcv rna level > 10,000 iu/ml at screening
Description

Hepatitis C virus RNA assay Plasma

Type de données

boolean

Alias
UMLS CUI [1,1]
C1272251
UMLS CUI [1,2]
C0032105
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of severe, life-threatening or other significant sensitivity to any drug.
Description

Drug Allergy Severe Life Threatening | Drug Allergy Significant

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013182
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C2826244
UMLS CUI [2,1]
C0013182
UMLS CUI [2,2]
C0750502
females who were pregnant or planned to become pregnant, or breastfeeding, or gt4-infected males whose partners were pregnant or planning to become pregnant within 7 months (or per local rbv label) after their last dose of study drug/rbv.
Description

Pregnancy | Pregnancy, Planned | Breast Feeding | Gender Hepatitis C Genotype | Gender Partner Pregnancy | Gender Partner Planned Pregnancy

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0032992
UMLS CUI [3]
C0006147
UMLS CUI [4,1]
C0079399
UMLS CUI [4,2]
C0019196
UMLS CUI [4,3]
C1533728
UMLS CUI [5,1]
C0079399
UMLS CUI [5,2]
C0682323
UMLS CUI [5,3]
C0032961
UMLS CUI [6,1]
C0079399
UMLS CUI [6,2]
C0682323
UMLS CUI [6,3]
C0032992
recent history of drug or alcohol abuse that could preclude adherence to the protocol.
Description

Substance Use Disorder Excludes Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1,1]
C0038586
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C0525058
positive test result for hepatitis b surface antigen or anti-human immunodeficiency virus (hiv) antibodies.
Description

Hepatitis B surface antigen positive | HIV antibody positive

Type de données

boolean

Alias
UMLS CUI [1]
C0149709
UMLS CUI [2]
C0920548
Retour au début de la page

Similar models

Eligibility Hepatitis C, Chronic NCT01685203

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Gender Contraceptive methods | Postmenopausal state Duration
Item
females must be practicing specific forms of birth control on study treatment, or be postmenopausal for more than 2 years or surgically sterile
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0232970 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
Criteria Quantity Fulfill
Item
subjects must meet one of the following:
boolean
C0243161 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
Therapy naive | Antiviral Therapy Absent Hepatitis C
Item
treatment-naive: subject has never received antiviral treatment for hepatitis c infection or
boolean
C0919936 (UMLS CUI [1])
C0280274 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0019196 (UMLS CUI [2,3])
Therapeutic procedure Experience | Non-responder PEGINTERFERON/RIBAVIRIN | Partial responder PEGINTERFERON/RIBAVIRIN | Relapse PEGINTERFERON/RIBAVIRIN
Item
treatment experienced (prior null responders, partial responders or relapsers to pegifn/rbv);
boolean
C0087111 (UMLS CUI [1,1])
C0596545 (UMLS CUI [1,2])
C0919875 (UMLS CUI [2,1])
C1875630 (UMLS CUI [2,2])
C4285679 (UMLS CUI [3,1])
C1875630 (UMLS CUI [3,2])
C0035020 (UMLS CUI [4,1])
C1875630 (UMLS CUI [4,2])
Body mass index
Item
body mass index (bmi) is ≥ 18 to < 38 kg/m^2.
boolean
C1305855 (UMLS CUI [1])
Chronic Hepatitis C Genotype Duration | Liver Cirrhosis | Liver Cirrhosis Absent | Hepatitis C Genotype Duration | Liver Cirrhosis Absent
Item
chronic hcv genotype 1b infection/with or without cirrhosis or hcv genotype 4 infection/without cirrhosis for at least 6 months prior to study screening.
boolean
C0524910 (UMLS CUI [1,1])
C1533728 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
C0023890 (UMLS CUI [2])
C0023890 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0019196 (UMLS CUI [4,1])
C1533728 (UMLS CUI [4,2])
C0449238 (UMLS CUI [4,3])
C0023890 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Hepatitis C virus RNA assay Plasma
Item
subject has plasma hcv rna level > 10,000 iu/ml at screening
boolean
C1272251 (UMLS CUI [1,1])
C0032105 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Drug Allergy Severe Life Threatening | Drug Allergy Significant
Item
history of severe, life-threatening or other significant sensitivity to any drug.
boolean
C0013182 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C2826244 (UMLS CUI [1,3])
C0013182 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
Pregnancy | Pregnancy, Planned | Breast Feeding | Gender Hepatitis C Genotype | Gender Partner Pregnancy | Gender Partner Planned Pregnancy
Item
females who were pregnant or planned to become pregnant, or breastfeeding, or gt4-infected males whose partners were pregnant or planning to become pregnant within 7 months (or per local rbv label) after their last dose of study drug/rbv.
boolean
C0032961 (UMLS CUI [1])
C0032992 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
C0079399 (UMLS CUI [4,1])
C0019196 (UMLS CUI [4,2])
C1533728 (UMLS CUI [4,3])
C0079399 (UMLS CUI [5,1])
C0682323 (UMLS CUI [5,2])
C0032961 (UMLS CUI [5,3])
C0079399 (UMLS CUI [6,1])
C0682323 (UMLS CUI [6,2])
C0032992 (UMLS CUI [6,3])
Substance Use Disorder Excludes Protocol Compliance
Item
recent history of drug or alcohol abuse that could preclude adherence to the protocol.
boolean
C0038586 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
Hepatitis B surface antigen positive | HIV antibody positive
Item
positive test result for hepatitis b surface antigen or anti-human immunodeficiency virus (hiv) antibodies.
boolean
C0149709 (UMLS CUI [1])
C0920548 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial